Abstract
This study is about an anticancer drug called ponatinib which is a tyrasine kinase inhibitor
given with chemotherapy to children, teenagers, and young adults up to 21 years of age with
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia who have relapsed or are
resistant to other treatment.
The main aims of this study are to confirm the highest dose of ponatinib tablets and
minitablet capsules that can be given to participants with acceptable side effects, and to
evaluate if participant's leukemia achieves remission.
Participants will take ponatinib tablets with chemotherapy. For participants who cannot
swallow tablets, a minitablet form of the ponatinib will be provided. Participants will take
ponatinib for 10 weeks in combination with chemotherapy (reinduction and consolidation
blocks) and will be followed up for at least 3 years.
